

Jeffrey S Weber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4771236/publications.pdf>

Version: 2024-02-01

120
papers

41,432
citations

41258

49
h-index

35952

97
g-index

121
all docs

121
docs citations

121
times ranked

34015
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 495-508.	21.5	120
2	Deep Learning and Pathomics Analyses Reveal Cell Nuclei as Important Features for Mutation Prediction of BRAF-Mutated Melanomas. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1650-1658.e6.	0.3	22
3	Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont <i>et al</i> ., 2022, 10, e004347.		0
4	American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach. <i>Endocrine Practice</i> , 2022, 28, 719-731.	1.1	12
5	Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?. <i>Journal of Neuro-Oncology</i> , 2022, 158, 471-480.	1.4	5
6	Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 131-140.	3.2	93
7	Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. <i>BMC Cancer</i> , 2021, 21, 57.	1.1	3
8	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2021, 27, 2571-2583.	3.2	22
9	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	1.3	57
10	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021, 19, 142.	1.8	1
11	Abstract CT008: Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow up. <i>Cancer Research</i> , 2021, 81, CT008-CT008.	0.4	2
12	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	0.8	145
13	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
14	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021, 157, 391-402.	1.3	13
15	Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2021, 10, 7457-7465.	1.3	11
16	Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. <i>European Journal of Cancer</i> , 2021, 158, 225-233.	1.3	8
17	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 3978-3992.	0.8	121
18	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	0.8	580

#	ARTICLE	IF	CITATIONS
19	390â€¦A global, molecular disease characterization initiative (MDCI) in oncology clinical trials. , 2021, 9, A423-A423.		0
20	Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. European Journal of Cancer, 2020, 137, 171-174.	1.3	11
21	P865â€¦Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies â€“ independent review committee data update. , 2020, , .		3
22	A proposal for score assignment to characterize biological processes from mass spectral analysis of serum. Clinical Mass Spectrometry, 2020, 18, 13-26.	1.9	2
23	Adjuvant nivolumab versus ipilimumab in resected stage IIIbâ€“C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 1465-1477.	5.1	330
24	TNFÎ± Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?. Clinical Cancer Research, 2020, 26, 2085-2086.	3.2	8
25	New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986â€“2016. American Journal of Public Health, 2020, 110, 731-733.	1.5	91
26	Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy. Frontiers in Immunology, 2020, 11, 164.	2.2	8
27	Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. , 2020, 8, e000842.		126
28	C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. , 2020, 8, e000234.		56
29	Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. , 2020, 8, e000356.		34
30	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
31	Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. Clinical Cancer Research, 2020, 26, 3384-3396.	3.2	24
32	Systemic Therapy for Melanoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 3947-3970.	0.8	190
33	Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.. Journal of Clinical Oncology, 2020, 38, 10006-10006.	0.8	32
34	A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.. Journal of Clinical Oncology, 2020, 38, 3094-3094.	0.8	5
35	Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2020, 38, TPS3166-TPS3166.	0.8	4
36	Using autoantibody signatures to predict immunotherapy discontinuation in melanoma patients.. Journal of Clinical Oncology, 2020, 38, 3069-3069.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Lack of evidence to support large-panel genomic testing in treatment selection for malignant melanoma.. Journal of Clinical Oncology, 2020, 38, e22027-e22027.	0.8	0
38	Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma.. Journal of Clinical Oncology, 2020, 38, 10052-10052.	0.8	4
39	Novel blood-based biomarker predicting severe toxicity in melanoma anti-CTLA-4 immunotherapy treatment.. Journal of Clinical Oncology, 2020, 38, 3077-3077.	0.8	0
40	Impact of immune checkpoint and BRAF inhibitors on the incidence of second primary malignancies (SPM) in melanoma.. Journal of Clinical Oncology, 2020, 38, 12061-12061.	0.8	0
41	Using machine learning to predict immunotherapy response in advanced melanoma.. Journal of Clinical Oncology, 2020, 38, 10010-10010.	0.8	1
42	681â€¦Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors. , 2020, , .		0
43	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer, 2019, 119, 1-10.	1.3	132
44	Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Medicine, 2019, 11, 61.	3.6	134
45	Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.. Journal of Clinical Oncology, 2019, 37, 100-100.	0.8	44
46	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.. Journal of Clinical Oncology, 2019, 37, 2512-2512.	0.8	18
47	Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144,) Tj ETQq1 1 0.784314 rgBT /Overlock including anti-PD-1.. Journal of Clinical Oncology, 2019, 37, 2518-2518.	0.8	71
48	Using machine learning algorithms to predict response and toxicity to immune checkpoint inhibitors (ICIs) in melanoma patients.. Journal of Clinical Oncology, 2019, 37, 2581-2581.	0.8	3
49	The relationship between obesity and immunotherapy: It's complicated.. Journal of Clinical Oncology, 2019, 37, 9562-9562.	0.8	4
50	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. Journal of Clinical Oncology, 2019, 37, 9584-9584.	0.8	6
51	Effects of online education on the identification and management of immune-related adverse events over time.. Journal of Clinical Oncology, 2019, 37, e18224-e18224.	0.8	2
52	The solved and unresolved issues of melanoma staging: A comparison of American Joint Committee on Cancer (AJCC) 7th versus 8th edition.. Journal of Clinical Oncology, 2019, 37, 9578-9578.	0.8	0
53	First-line stereotactic radiosurgery combined with systemic targeted and immune checkpoint inhibitor therapy in melanoma patients with newly diagnosed brain metastases.. Journal of Clinical Oncology, 2019, 37, e13577-e13577.	0.8	0
54	Online education about immunotherapy for melanoma: Outcomes over time.. Journal of Clinical Oncology, 2019, 37, 10533-10533.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i> -V600E-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5516-5524.	3.2	55
56	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	3.2	222
57	Recent advances in adjuvant therapy for patients with melanoma. <i>ESMO Open</i> , 2018, 3, e000337.	2.0	0
58	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. <i>Cell</i> , 2018, 173, 624-633.e8.	13.5	113
59	Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma. <i>Cancer</i> , 2018, 124, 2254-2255.	2.0	0
60	Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. <i>Cancer</i> , 2018, 124, 297-305.	2.0	76
61	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 79-86.	1.6	61
62	The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 381-392.	2.0	113
63	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 383-390.	0.8	431
64	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	0.8	2,691
65	Frontiers in pigment cell and melanoma research. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 728-735.	1.5	10
66	Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 44.	1.3	67
67	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	425
68	Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 6236-6247.	3.2	54
69	Immunotherapy in the adjuvant setting for high-risk melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 546-548.	0.3	1
70	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 393-403.	5.1	91
71	PD-1 and PD-L1 antibodies in cancer: current status and future directions. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 551-564.	2.0	253
72	Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. <i>Oncologist</i> , 2017, 22, 709-718.	1.9	221

#	ARTICLE	IF	CITATIONS
73	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 785-792.	0.8	930
74	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	13.9	1,752
75	Reply to F. Liang et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1968-1968.	0.8	0
76	Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2017, 35, 139-140.	0.8	22
77	Biomarkers for Checkpoint Inhibition. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 205-209.	1.8	11
78	Association of changes in T regulatory cells (Treg) during nivolumab treatment with melanoma outcome.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3031-3031.	0.8	3
79	Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600 mutant unresectable or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9505-9505.	0.8	7
80	Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9523-9523.	0.8	18
81	A phase I trial of panobinostat with ipilimumab in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9547-9547.	0.8	12
82	Final report of a pilot trial combining ipilimumab and adoptive cell therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 147-147.	0.8	1
83	Evaluation of an online tool providing management guidance for adverse events associated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18131-e18131.	0.8	0
84	Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3017-3017.	0.8	0
85	Association of distinct baseline tissue biomarkers with response to nivolumab (NIVO) and ipilimumab (IPI) in melanoma: CheckMate 064.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9515-9515.	0.8	1
86	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	2.0	82
87	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	3.8	857
88	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	13.9	1,140
89	Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. <i>Oncologist</i> , 2016, 21, 1230-1240.	1.9	212
90	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	2.0	288

#	ARTICLE	IF	CITATIONS
91	A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. , 2016, 4, 85.		18
92	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2016, 17, 943-955.	5.1	293
93	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology, 2016, 34, 1510-1517.	0.8	627
94	Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clinical Cancer Research, 2016, 22, 886-894.	3.2	705
95	Modeling the cost of immune checkpoint inhibitor-related toxicities.. Journal of Clinical Oncology, 2016, 34, 6627-6627.	0.8	11
96	Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.. Journal of Clinical Oncology, 2016, 34, 9503-9503.	0.8	98
97	Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM).. Journal of Clinical Oncology, 2016, 34, 9507-9507.	0.8	5
98	Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064).. Journal of Clinical Oncology, 2016, 34, 9517-9517.	0.8	1
99	Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. Journal of Clinical Oncology, 2016, 34, 9525-9525.	0.8	2
100	Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.. Journal of Clinical Oncology, 2016, 34, 9544-9544.	0.8	2
101	Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL).. Journal of Clinical Oncology, 2016, 34, 9586-9586.	0.8	10
102	Selective histone deacetylase inhibition augments melanoma immunotherapy.. Journal of Clinical Oncology, 2016, 34, e14521-e14521.	0.8	1
103	In vitro and in vivo anti-melanoma activity of ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties.. Journal of Clinical Oncology, 2016, 34, e21075-e21075.	0.8	2
104	ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, TPS3107-TPS3107.	0.8	13
105	Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget, 2016, 7, 23885-23896.	0.8	23
106	Epigenetic control of CD4/CD8 lineage commitment and resistance to tumor infiltrating lymphocyte adoptive cell therapy for metastatic melanoma.. Journal of Clinical Oncology, 2016, 34, 3008-3008.	0.8	0
107	Toxicities of Immunotherapy for the Practitioner. Journal of Clinical Oncology, 2015, 33, 2092-2099.	0.8	521
108	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 375-384.	5.1	2,353

#	ARTICLE	IF	CITATIONS
109	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2015, 33, 278-284.	0.8	102
110	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1889-1894.	0.8	1,809
111	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq1 1 0,784314 rgBT /Over	5.1	1,093
112	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet, The</i> , 2014, 384, 1109-1117.	6.3	1,588
113	Safety and Tumor Responses with Lambrolizumab (Anti-“PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	13.9	3,128
114	Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. <i>Journal of Clinical Oncology</i> , 2012, 30, 2691-2697.	0.8	1,272
115	Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 896-906.	3.2	185
116	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723.	13.9	13,065
117	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 5591-5598.	3.2	531
118	Ipilimumab: controversies in its development, utility and autoimmune adverse events. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 823-830.	2.0	216
119	Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5950-5956.	0.8	442
120	Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 741-750.	0.8	433